Advanced Multi-omics and -System Approaches to Identify Novel Biomarkers for SMA - Approcci Avanzati Multi-omici e Sistemici Per Identificare Nuovi Biomarcatori Per la SMA
Spinal muscular atrophy (SMA) is an inherited neuromuscular disorder caused by mutations in the SMN1 gene, leading to motor neuron degeneration and progressive muscle atrophy. Despite recent advances in therapeutic options, the clinical management of SMA remains challenging due to the heterogeneity of disease progression and variability in treatment response. This study aims to identify and validate novel biomarkers to improve the diagnosis, prognosis, and therapeutic monitoring of patients with SMA through a multi-omics and translational research approach.
• Genetically confirmed diagnosis of SMA, with homozygous deletion or mutation of the SMN1 gene, for symptomatic patients.
• Diagnosis of SMA through newborn screening, with genetic confirmation, for newborns.
• Ability of parents/legal guardians to provide informed consent for minor patients.
• Willingness to undergo the study procedures, including blood sampling and collection of biological specimens.